lithium and semaglutide Is it safe to use together with therapy? PDF) Lithium toxicity following a

This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist, in the treatment of obesity and its related comorbidities

GLP-1 drugs mimic a gut hormone with effects that are especially relevant during menopause.

The primary endpoint was the percentage weight loss at six months (M6) compared to baseline

Key Highlights: GLP-1s Reshape the Market: Sales of GLP-1 drugsoriginally for type-2 diabetes but now widely prescribed for weight managementdrove much of the first-quarter growth

Supplied in a 5mg lyophilized vial for laboratory research only

A study of health insurance claims found a 44% reduction in hospitalizations for GLP-1 users